Es posible que usted sea propietario de Eli Lilly (LLY), una farmacéutica con un valor aproximado de 1,05 billones de dólares, además de fondos que ya siguen el S&P 500. Una sola acción puede convertirse en una gran parte de su dinero, por lo que sus movimientos diarios son importantes para todos. ¿Las acciones de Eli Lilly son adecuadas para el riesgo que ya conlleva?

Eli Lilly (NYSE:LLY) obtiene la aprobación de la FDA para la insulina Onswik una vez a la semana y presenta datos de retatrutida y Foundayo en la reunión europea sobre diabetes en Milán.

Eli Lilly (NYSE:LLY) informa un análisis indirecto que muestra que Zepbound 10 mg y 15 mg se asocian con una mayor pérdida de peso que Wegovy HD.

Eli Lilly and Company (NYSE:LLY) reported results from an indirect treatment comparison in which Foundayo, or orforglipron, 17. 2 mg was associated with greater reductions in body weight and blood sug...

Eli Lilly (NYSE:LLY) enters today’s market discussion as sector themes, operations, and broader conditions draw attention.

Durante estos tiempos de mucha actividad, vale la pena estar al tanto de las últimas oportunidades de ganancias. Y la publicación del blog de hoy debería ser un excelente lugar para comenzar.

Eli Lilly says Foundayo beat oral semaglutide in weight loss and A1C for type 2 diabetes in new analysis.

Eli Lilly (NYSE:LLY) received FDA Breakthrough Therapy designation for its next-generation KRAS G12C inhibitor olomorasib in advanced pancreatic cancer. The pharmaceutical group launched a global Change the Course program aimed at broadening access to its diabetes and obesity treatments in low and middle income countries. CEO Dave Ricks signaled a shift toward larger acquisitions in new therapeutic areas that extend beyond the firm’s current obesity focus. The Breakthrough Therapy status for...

Two new studies on the experimental drug retatrutide show it helps overweight people lose weight, whether or not they have diabetes.

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from a new analysis showing that Foundayo...

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced detailed results from...

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Foundayo (orforglipron), today announced results from a new analysis showing that Zepbound...